Overview
AMC Sciences stands as the exclusive hospital-based accelerator in South Korea, founded by leading researchers at Asan Medical Center with a wealth of knowledge and some of the richest clinical experience in the country.
Established in January 2023 within the Asan Life Sciences Institute with the support of the Asan Foundation, AMC Sciences is committed to the exploration and development of treatments for diverse intractable diseases.
Utilizing the extensive clinical data and research infrastructure of Asan Medical Center, AMC Sciences fosters startup growth by cultivating innovative therapies through open innovation.
Business Model
AMC Sciences strategically investigates and validates emerging drug technologies through the Central Laborator.
This process involves meticulous evaluation to inform investment decisions and facilitate the advancement of nascent assets through
internal Company-in-Company (CIC) prototype entities.
Upon achieving success, these prototype companies undergo a structured transition to independence,
guided by a planned entrepreneurial approach spearheaded by AMC Sciences.
-
Central Lab
Exploring and validating new drug technologies
-
Prototype Company
Operates as an internal organization (CIC) and supports early asset development
-
Company Spin-off
AMC Science-led Planning Start-up